Background: In the context of the DAWN-2 initiatives, the BENCH-D Study aims to test a model of regional benchmarking to improve not only the quality of diabetes care, but also patient-centred outcomes.
Introduction
The prevention of diabetes and control of its micro-and macrovascular complications has become one of the main public health challenges for the 21 st century, with the aim of attaining a significant reduction in the huge premature morbidity and mortality it causes, with a parallel reduction in health care costs (Shaw et al. 2010) . To this purpose, in addition to the implementation of strategies for diabetes prevention through lifestyle modification, a more aggressive control of the most important risk factors is urgently needed (American Diabetes Association 2009). In fact, despite strong evidence that pharmacological interventions play an important role in preventing complications in individuals with diabetes, the mere dissemination of evidence-based guidelines often fails to deeply influence clinical practice.
The considerable pressure on health care systems to provide high-quality care while controlling costs has led several public and private health care organizations to promote initiatives to measure and improve the quality of care for patients with diabetes (Peters et al. 1996; TRIAD Study Group 2002; Ilag et al. 2003; Saaddine et al. 2002 Saaddine et al. , 2006 . Quality measures identified include process and intermediate outcome indicators, selected under the assumption that they are linked to downstream health outcomes. These measures have been widely utilized to monitor quality of care and promote continuous quality improvement initiatives (Saaddine et al. 2002 (Saaddine et al. , 2006 .
In Italy, the Associazione Medici Diabetologi (AMD) has implemented a continuous improvement effort involving over 300 diabetes clinics throughout the Country (Rossi et al. 2008) . To this purpose, AMD identified a set of quality indicators, including process and intermediate outcome measures. All indicators are compared with reference values, or "gold standard", established by identifying the best performers. By fixing as reference the results obtained by the best performers, specialists can easily realize the real margin of improvement made possible by simply increasing the level of attention to disease monitoring and treatment. The AMD Annals initiative allows a thorough description of the quality of care delivered every year by specialist structures to over 500.000 patients (Arcangeli et al. 2013) . In additional to cumulative analyses, AMD Annals also provide sub-analyses at the regional level, to facilitate the local use of the data for quality improvement initiatives. The initiative has already proven to be effective in improving several quality of care indicators (Nicolucci et al. 2010) .
Nevertheless, more structured benchmarking activities, involving discussion with clinicians, detection of obstacles at the local level, and identification of possible solutions are likely to produce further improvements in diabetes care. To this respect, a preliminary experience carried out in Sicily by a network of diabetes clinics documented a tangible improvement in the quality of diabetes care over 5 years (Club Diabete Sicili@ 2008) .
In recent years, there has been an increasing recognition of patient-centered care as the best model to ensure a care respectful of, and responsive to patient preferences, needs, and values (Glasgow et al. 2008) . The focus on patients' perspective has thus become particularly relevant. Despite the consensus that patient-centered care is an essential component of good diabetes care, most diabetes performance measures are solely based on clinical measures, and do not include psychosocial items. The need to include psychosocial aspects in the quality model of diabetes care has been clearly emphasized by the international Diabetes Attitudes, Wishes, and Needs (DAWN) Program. The DAWN Study has clearly shown that people with diabetes across 13 countries have major psychosocial issues that are not adequately addressed in the existing health care systems (Conference Report 2004; International Diabetes Federation 2004; Peyrot et al. 2005a; Skovlund and Peyrot 2005; Wroe 2006 ). Given these premises, the BENCH-D Study (Benchmarking Network for Clinical and Humanistic Outcomes in Diabetes) was designed to test a model of regional benchmarking activity aimed at improving not only the quality of diabetes care, but also patient-centered outcomes. The BENCH-D study is integral part of the DAWN-2 initiatives (Peyrot et al. 2013) in Italy.
Methods

Objectives
Aims of the BENCH-D study are:
1. To tests the feasibility of a regional model for quality improvement, based on a deep analysis of regional data coupled with a structured process for the identification of priority actions; 2. To identify a core set of patient centered indicators to be adopted in conjunction with clinical indicators; 3. To evaluate the impact of the benchmarking initiative in improving both clinical and patientcentered quality indicators.
Setting
The study involves 32 diabetes clinics in four different Italian regions (Piedmont, Marche, Lazio, and Sicily). Regions have been selected to reflect different levels of performance in terms of process and intermediate outcome measures, based on the information collected in the previous analyses of AMD Annals.
Clinical data collection
Following the methodology applied in the AMD Annals initiative (Rossi et al. 2008; Arcangeli et al. 2013; Nicolucci et al. 2010) , presence of micro/macroalbuminuria, and GFR ≤60 ml/min.
Indicators of treatment intensity/appropriateness take into consideration the use of pharmacological treatments in relation to the achievement of the targets. This set includes: no insulin treatment in spite of HbA1c > 9.0% (75 mmol/mol); HbA1c >9.0% (75 mmol/mol) in spite of insulin treatment; no lipid-lowering agents in spite of LDL-c ≥130 mg/dl; LDL-c ≥130 mg/dl in spite of lipidlowering treatment; no antihypertensive treatments in spite of BP ≥ 140/90 mmHg; BP ≥ 140/90 mmHg in spite of antihypertensive treatment; no ACE-inhibitors (ACE-I) and/or Angiotensin Receptor Blockers (ARBs) in spite of micro/macroalbuminuria.
A quality of care summary score (Q score) is also calculated. The Q score has been developed and validated in two previous studies (De Berardis et al. 2008; Rossi et al. 2011) ; it is based on a combination of process and intermediate outcome indicators relative to HbA1c, blood pressure, LDL-cholesterol and microalbuminuria. The score ranges between 0 and 40; the higher the score, the better the quality of care. The risk to develop a new cardiovascular event within 3 years was shown to be 80% higher in patients with a score <15 and 20% higher in those with a score between 15 and 25, as compared to those with a score >25 (De Berardis et al. 2008; Rossi et al. 2011 ).
Quality of life and patient satisfaction evaluation
Information on quality of life and patient satisfaction is collected using ad hoc questionnaires. The questionnaire includes ten instruments, partially derived from the DAWN-2 study (Peyrot et al. 2013) .
Standardized instruments were incorporated into the questionnaires in original or shortened forms: SF-12 health survey, WHO Well-Being Index (WHO-5), Diabetes Empowerment Scale-Short Form (DES-SF), Problem Areas in Diabetes Scale 5 (PAID-5), Patient Assessment of Chronic Illness Care-Short Form (PACIC-SF), Health Care Climate Short Form (HCC-SF), Global Satisfaction with Diabetes Treatment (GSDT), Summary of Diabetes SelfCare Activities measure (SDSCA-6); Barriers to Medications (BM), Perceived Social Support (PSS).
All the questionnaires, with the exception of the already previously validated WHO-5 Well-Being Index (Bech et al. 1996; Hajos et al. 2013) , have undergone a rigorous process of translation into the Italian language and psychometric validation specifically for the BENCH-D study. All the scale scores, with the exception of SDSCA-6, range between 0 and 100, with higher values indicating a higher level of the dimension measured.
-SF-12 Health Survey (SF-12): it is a widely used generic health status measure (Gandek et al. 1998 ). It includes 12 items which can be aggregated into two summary measures: the Physical (PCS) and Mental (MCS) Component Summary scores. Both scores are normalized to a general population mean of 50 and a standard deviation of 10. -WHO-5 Well-Being Index (WHO-5): It assesses the psychological well-being, a core component of overall quality of life (Bech et al. 1996; Hajos et al. 2013 (Anderson et al. 2000 . An effective diabetes management requires an empowered diabetes patient, who is able to take personal charge of parts of the care plan, yet the extent to which educational and pedagogic efforts of the healthcare team are effective in empowering the patient is rarely measured. The instrument includes 8 items with responses on a fivepoint Likert scale. -Problem Areas in Diabetes -Short form (PAID-5):
PAID evaluates the emotional diabetes distress, i.e. patients specific worries and negative emotions related to their diabetes (McGuire et al. 2010; Polonsky et al. 1995; Welch et al. 2003) . It also complements the general well-being assessment with vital information about the patient's acceptance of and coping with diabetes-specific issues. The instrument has been applied in more than a hundred studies and in the DAWN MIND (Monitoring Individual Needs in People with Diabetes) program across 10 countries (McGuire et al. 2010 (Glasgow et al. 2005; Gugiu et al. 2009 ). In this study we used the short-form version of the questionnaire, including 11 items with responses on a five-point Likert scale. -Health Care Climate Questionnaire -Short form (HCC-SF): it evaluates the extent to which clinicians tend to favor the autonomy of the patient or, instead, tend to assume a paternalistic attitude towards the patient (Williams et al. 2004 ). This instrument has been used in many studies on different diseases, including diabetes, and has proven to be able to predict an improvement in metabolic control (Schafer et al. 1986 ). The study uses a short version of the questionnaire, consisting of 6 questions, with responses on 7-point Likert scale. -Global Satisfaction with Diabetes Treatment (GSDT): It assesses the perceived impact of medication on daily life and psychological well being, in addition to overall satisfaction for the pharmacological treatment (Brod et al. 2006 ). It represents a very important element in determining the acceptance by the patient and adherence to therapy. The questionnaire was developed as part of the DAWN Study, and consists of 7 items with responses on 5-point Likert scales. -Summary of Diabetes Self-care Activities (SDSCA-6): it assesses health behaviours, notoriously difficult to evaluate reliably. The instrument has been shown to add relevant and useful information in the context of diabetes studies, even though data must be interpreted with caution as they are self-reported (Toobert et al. 2000) . The version of the SDSCA-6 includes 6 selected items with responses on 8-point Likert scales, indicating the number of days (from 0 to 7) in a week the patient adheres with the recommended behaviour. Each item is treated individually. -Barriers to Medications (BM): Compliance to medication is considered a key reason for suboptimal outcomes (Brod et al. 2006; Snoek et al. 2007; Anderson et al. 2004 Information on socio-demographic characteristics (age, gender, nationality, level of school education, working status, living status) are also collected through the questionnaire.
Questionnaires are anonymous, filled in by the patients on the occasion of a routine visit and sent to the coordinating center using sealed envelopes. The link between clinical and patient reported data is ensured by a univocal numerical code.
Patient recruitment
All patients seen in the participating centers during the previous 12 months are included in the evaluation of clinical indicators. Patient centered outcomes are evaluated in a sub-sample of patients, selected using random sampling lists, stratified by diabetes treatment (oral agents, insulin, insulin and oral agents). An additional sample of patients with newly diagnosed diabetes (diagnosis made in the last 12 months) has been also identified. Within each treatment group, the sample has been further stratified by gender.
Regional meetings
In each region, 5 meetings are scheduled, involving all the health care professionals participating in the initiative (diabetologists, nurses, dietitians).
In the first meeting, the aims and the operational aspects of the study were illustrated and discussed with participants.
The second meeting was focused on the discussion of the results relative to clinical indicators produced by the AMD Annals at the national and regional level. The "best performers" approach was used to compare the overall results obtained at the regional level with those obtained in those centers reaching the highest rates of performance for process and outcome measures. The session was organized according to a standardized structure. After the illustration of the results, each participant was asked to identify the three main problems emerging from the data. All the problems identified were then assigned by the participants a score from 0 to 10 for their relevance and a score from 0 to 10 for the concrete possibility to act on the problem. Problems were then ranked, and the first three were selected. Following the same procedure, three major obstacles causing the problems were identified and possible solutions proposed. The process led to the definition of a regional mandate, to be implemented in the following 12 months. The mandate did not require a radical change in the usual clinical practice, but rather an optimization of the work already done and a more appropriate use of the available resources.
The third meeting was focused on patient centered outcomes. Following the same methodology of the previous meeting, results of the quality of life and satisfaction survey were discussed, problems/barriers were identified, and possible solutions/actions proposed. Eighteen months after the third meeting, clinical data will be extracted again, allowing a first evaluation of the impact of the initiative on clinical indicators. The impact of benchmarking activities on patient centered outcomes will be evaluated following a second survey conducted with the same patients participating in the first one. The results will be discussed on the occasion of the fourth meeting. Improvements registered and problematic areas where no improvements in performance will be documented will represent the core for discussion. Elements that have facilitated or represented an obstacle to improvement will be analyzed in detail, and actions to improve quality of care will be identified.
A final data collection on clinical indicators will be performed 12 months after the second clinical data extraction, and results will be discussed in the fifth meeting, which will represent the occasion for the assessment of the overall outcomes of the initiative. The results of this final assessment will be useful to identify the strengths and limitations of the approach adopted, and will help in better refining the overall approach before its extension to other regions.
The study design is reported in Table 1 .
Statistical analysis
Except for the SF-12 and the WHO-5, largely utilized in the Italian population, all the other quality of life scales have been translated, cross-culturally adapted and validated in Italian specifically for the BENCH-D study. The questionnaire was validated using a multitrait multi-item method (Ware et al. 1997 ). This method is used to determine whether each item in a scale is substantially related (r ≥0.40) to the total score computed from the other items in that scale (item convergent validity criterion). Internal-consistency reliability was estimated by the Cronbach's alpha coefficient, with a minimum value of 0.70 considered as acceptable. Furthermore, the percentages of respondents achieving either the highest score (ceiling) and lowest score (floor) were calculated. Patient characteristics and clinical indicators are described as mean and standard deviation or frequencies.
Scale scores are summarized as mean and standard deviation. All the data have been centrally analyzed anonymously.
Ethics considerations
The study protocol was approved by local ethics committees of participating centers. A written informed consent was obtained by all patients before the administration of the questionnaires.
The protocol was approved by the institutional review board of the Mario Negri Sud Foundation and by the scientific committee of the Associazione Medici Diabetologi.
Results
Recruitment
Overall, 32 centers extracted by the electronic clinical record system information on 78,854 patients with type 2 diabetes for benchmarking activities based on clinical indicators, while 26 centers enrolled 2,390 patients for the validation and evaluation of patient centered outcomes. Socio-demographic and clinical characteristics of the patients who filled in the questionnaire are summarized in Table 2 .
Validation of the questionnaires
The validation process was performed using all the questionnaires filled in by 2,390 patients enrolled. All the questionnaires showed excellent psychometric characteristics; for all scales, the Cronbach's alpha coefficient largely exceeded the minimum accepted value of 0.70 (Table 3) . On the same line, item-scale correlation was extremely satisfactory for all the scales. Percentages at ceiling and floor were equal to 0% for DES-SF, HCC-SF, PACIC-SF, GSDT, PSS, and BM and in an acceptable range for PAID-5 (10.2% at floor and 0% at ceiling).
Regional meetings
Meetings for the structured discussion of clinical and humanistic indicators have been held between September and October 2011. The approach adopted led to the identification of different priorities for intervention in the four regions, reflecting different organizational characteristics and specific needs.
The operational protocol has been officially launched in March 2012. The biggest challenge identified in all regions was to test innovative ways of communication with the patient, and to deal with his/her psychosocial needs. Table 4 shows as an example the problems and solutions proposed in one of the regions.
Discussion
The BENCH-D study allows the field testing of benchmarking activities based on a structured discussion of quality indicators, selection of priorities, and identification pertinent actions. Furthermore, the study includes for the first time in a benchmarking initiative a set of validated patient centered indicators and will document whether it is possible to improve not only clinical indicators, but also patient well-being and satisfaction with the care received. If successful, the initiative could be extended to other Italian regions, as well as to other health care systems. As a whole, this project can make an important contribution in promoting patient-centered care and improving the quality of diabetes care. Competing interests AN is a member of the advisory board of Novo Nordisk, Novartis, Merk Sharp & Dohme. He has received speaker fees from Novo Nordisk, Novartis, Merk Sharp & Dohme; GM is an employee of Novo Nordisk, Rome, Italy; SES is an employee of Novo Nordisk A/S, Copenhagen, Denmark. All other authors declare that they have no conflict of interest.
Authors' contributions AN conceived the study, AN and MCR designed the study protocol, and SG and GV contributed to the study design. GV and BP researched data. MCR and BP coordinate the study. GM supported the study. AN, MCR, and BP wrote the manuscript, FP and GL performed the statistical analyses. GM, SS, SG and GV revised critically and approved the manuscript. All authors read and approved the final manuscript.
